PMID- 37378080
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230701
IS  - 1745-1981 (Print)
IS  - 1740-4398 (Electronic)
IS  - 1740-4398 (Linking)
VI  - 12
DP  - 2023
TI  - Real-world experience of cabozantinib in Asian patients with advanced renal cell 
      carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or 
      immune-checkpoint inhibitors.
LID - 10.7573/dic.2023-4-1 [doi]
LID - 2023-4-1
AB  - BACKGROUND: There is a lack of real-world data on the use of cabozantinib in 
      Asian patients with metastatic renal cell carcinoma. METHODS: We conducted a 
      retrospective study to investigate the toxicity and efficacy of cabozantinib in 
      this patient population who progressed on tyrosine kinase inhibitors and/or 
      immune-checkpoint inhibitors from six oncology centres in Hong Kong. The primary 
      endpoint was the incidence of serious adverse events (AEs) attributed to 
      cabozantinib. Secondary safety endpoints included dose reductions and AE-led 
      treatment terminations. Secondary effectiveness endpoints included overall 
      survival, progression-free survival, and objective response rate. RESULTS: A 
      total of 24 patients were included. Half received cabozantinib as a third-line or 
      later-line treatment, whilst 50% received prior immune-checkpoint inhibitors, 
      primarily nivolumab. Overall, 13 (54.2%) patients reported at least one 
      cabozantinib-related AE of grades 3-4. The most commonly reported AEs were 
      hand-foot skin reactions (9; 37.5%) and anaemia (4; 16.7%). Fifteen (65.2%) 
      patients required dose reductions. Three patients discontinued treatment because 
      of AEs. The median progression-free survival and overall survival were 10.3 
      months and 13.2 months, respectively; 6 (25%) patients achieved partial 
      responses, and 8 (33.3%) achieved stable disease. CONCLUSION: Cabozantinib was 
      generally well tolerated and efficacious in Asian patients with metastatic renal 
      cell carcinoma who were heavily pretreated.
CI  - Copyright (c) 2023 Poon DMC, Chan K, Leung AKC, Ng B, Cheung FY, Siu SWK, Hong Kong 
      Society of Uro-Oncology.
FAU - Poon, Darren Mc
AU  - Poon DM
AD  - Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong SAR, 
      China.
AD  - Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University 
      of Hong Kong, Hong Kong SAR, China.
FAU - Chan, Kuen
AU  - Chan K
AD  - Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong 
      Kong SAR, China.
FAU - Leung, Angus Kwong-Chuen
AU  - Leung AK
AD  - AMO Oncology Centre, Hong Kong SAR, China.
FAU - Ng, Brian
AU  - Ng B
AD  - Department of Oncology, Princess Margaret Hospital, Hong Kong SAR, China.
FAU - Cheung, Foon-Yiu
AU  - Cheung FY
AD  - Hong Kong Integrated Oncology Centre, Hong Kong SAR, China.
FAU - Siu, Steven Wai-Kwan
AU  - Siu SW
AD  - Department of Clinical Oncology, Queen Mary Hospital, Hong Kong SAR, China.
CN  - Hong Kong Society of Uro-Oncology
LA  - eng
PT  - Journal Article
DEP - 20230621
PL  - England
TA  - Drugs Context
JT  - Drugs in context
JID - 101262187
PMC - PMC10291967
OTO - NOTNLM
OT  - immuno-oncology
OT  - metastatic renal cell carcinoma
OT  - real-world effectiveness
OT  - sequential therapies
OT  - targeted therapy
OT  - tyrosine kinase inhibitors
OT  - vascular endothelial growth factor receptor
COIS- Disclosure and potential conflicts of interest: The authors declare that they 
      have no conflicts of interest relevant to this manuscript. The International 
      Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests 
      form for the authors is available for download at: 
      https://www.drugsincontext.com/wp-content/uploads/2023/05/dic.2023-4-1-COI.pdf
EDAT- 2023/06/28 13:09
MHDA- 2023/06/28 13:10
PMCR- 2023/06/21
CRDT- 2023/06/28 09:28
PHST- 2023/04/03 00:00 [received]
PHST- 2023/05/17 00:00 [accepted]
PHST- 2023/06/28 13:10 [medline]
PHST- 2023/06/28 13:09 [pubmed]
PHST- 2023/06/28 09:28 [entrez]
PHST- 2023/06/21 00:00 [pmc-release]
AID - dic-2023-4-1 [pii]
AID - 10.7573/dic.2023-4-1 [doi]
PST - epublish
SO  - Drugs Context. 2023 Jun 21;12:2023-4-1. doi: 10.7573/dic.2023-4-1. eCollection 
      2023.